SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Daytrading Canadian stocks in Realtime -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Hamlin who wrote (20649)8/20/1999 11:57:00 AM
From: Cameron  Respond to of 62348
 
BII - A couple buyers have pulled their orders at the $7.15 support level. If a few more follow suit - which is what I would do given the current lack of MOMO, the floor may collapse. If it breaks through the floor may still be a good shorting op.



To: Kevin Hamlin who wrote (20649)8/20/1999 1:07:00 PM
From: keith massey  Read Replies (1) | Respond to of 62348
 
Kevin

In the news from Aug 4

Glyko Biomedical's 33.3-per-cent-owned affiliate, BioMarin Pharmaceutical Inc., has appointed John L. Jost, as vice-president of manufacturing.

I thought when they did the IPO the shares increased, which lowered their share from 41 to 33%. Of course this is quick DD so I could be wrong.

Best Regards
KEITH


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News